KR0137371B1 - 물질중독에 대한 치료용 조성물 - Google Patents

물질중독에 대한 치료용 조성물

Info

Publication number
KR0137371B1
KR0137371B1 KR1019890012363A KR890012363A KR0137371B1 KR 0137371 B1 KR0137371 B1 KR 0137371B1 KR 1019890012363 A KR1019890012363 A KR 1019890012363A KR 890012363 A KR890012363 A KR 890012363A KR 0137371 B1 KR0137371 B1 KR 0137371B1
Authority
KR
South Korea
Prior art keywords
therapeutic composition
substance poisoning
substance
poisoning
buspyrone
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019890012363A
Other languages
English (en)
Korean (ko)
Other versions
KR900002776A (ko
Inventor
에이치. 가윈 프랭크
바이크 로버트
알더디스 마르크
쉬윔머 제프리
Original Assignee
아이삭 자아코브스키
브리스톨-마이어즈 스쿼브 컴패니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이삭 자아코브스키, 브리스톨-마이어즈 스쿼브 컴패니 filed Critical 아이삭 자아코브스키
Publication of KR900002776A publication Critical patent/KR900002776A/ko
Application granted granted Critical
Publication of KR0137371B1 publication Critical patent/KR0137371B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1019890012363A 1988-08-30 1989-08-29 물질중독에 대한 치료용 조성물 Expired - Fee Related KR0137371B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US23844088A 1988-08-30 1988-08-30
US238.440 1988-08-30
US238,440 1988-08-30
US07/367,823 US5468749A (en) 1988-08-30 1989-06-16 Method for treatment of substance addiction
US367,823 1989-06-16

Publications (2)

Publication Number Publication Date
KR900002776A KR900002776A (ko) 1990-03-23
KR0137371B1 true KR0137371B1 (ko) 1998-04-25

Family

ID=22897905

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890012363A Expired - Fee Related KR0137371B1 (ko) 1988-08-30 1989-08-29 물질중독에 대한 치료용 조성물

Country Status (3)

Country Link
US (1) US5468749A (OSRAM)
KR (1) KR0137371B1 (OSRAM)
TW (1) TW263435B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6107330A (en) * 1995-08-07 2000-08-22 Daiichi Pharmaceutical Co., Ltd. Inhibitor for narcotic analgesic dependence/resistance acquisition
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
CA2957667A1 (en) 2005-07-06 2007-01-11 Sepracor Inc. Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders
US8097760B2 (en) * 2006-03-31 2012-01-17 Sunovion Pharmacuticals Inc. Preparation of chiral amides and amines
EP2429514A1 (en) * 2009-05-13 2012-03-21 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/ antagonists and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
DE3149842C2 (de) * 1981-12-16 1983-11-24 Großversandhaus Quelle Gustav Schickedanz KG, 8510 Fürth Stiefel
US4438119A (en) * 1982-12-23 1984-03-20 Mead Johnson & Company Method for alleviation of extrapyramidal motor disorders
US4634703A (en) * 1985-10-25 1987-01-06 Bristol-Myers Company Method for alleviation of panic disorders
US4640921A (en) * 1986-02-04 1987-02-03 Bristol-Myers Treatment of sexual dysfunction with buspirone
US4687772A (en) * 1986-10-07 1987-08-18 Bristol-Myers Company Method for improvement of short term memory
US4777173A (en) * 1987-03-25 1988-10-11 Bristol-Myers Company Method for treatment of alcohol abuse
US4800204A (en) * 1987-05-07 1989-01-24 Mueller Peter S Method of controlling tobacco use
DE3736974A1 (de) * 1987-10-31 1989-05-11 Troponwerke Gmbh & Co Kg Verwendung von 2-pyrimidinyl-1-piperazin-derivaten
US4788189A (en) * 1988-02-29 1988-11-29 Glazer Howard I Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking

Also Published As

Publication number Publication date
KR900002776A (ko) 1990-03-23
US5468749A (en) 1995-11-21
TW263435B (OSRAM) 1995-11-21

Similar Documents

Publication Publication Date Title
Jones The pharmacology of cocaine
JP4343948B2 (ja) 体重減少に影響を及ぼすための組成物
US5185329A (en) Method for treatment of substance addiction
US6077846A (en) Epibatidine and derivatives thereof as cholinergic receptor agonists and antagonists
JPS63255225A (ja) 酒精飲料濫用治療剤
JP4377586B2 (ja) 炎症性疾患治療用のニコチン性受容体アゴニスト
US4117161A (en) Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine
WO2015054730A1 (en) Compositions and methods of administering same
KR0137371B1 (ko) 물질중독에 대한 치료용 조성물
EP1485050B1 (en) A substance with sedative effect
PL196334B1 (pl) Zastosowanie agonistów receptorów GABA B i ich farmaceutycznie dopuszczalnych pochodnych w terapii abstynencji nikotynowej u uzależnionych od nikotyny pacjentów
EP0356997A2 (en) The use of buspirone for preparing pharmaceutical compositions for the treatment of substance addiction
ES2231162T3 (es) 3-ciclopropilmetoxi-4-difluorometoxi-n-(33,5-dicloropirid-4 il)benzamida en el tratamiento de la esclerosis multiple.
JP7265526B2 (ja) てんかん治療剤
JP2005513105A (ja) 臨床的うつ病を治療するためのデオキシペガニンの使用
US6221858B1 (en) Pyridyl-and pyrimidyl-piperazines in the treatment of substance abuse disorders
CZ217094A3 (en) Pharmaceutics which are antagonists of 5ht1a receptor for preparing a medicament for reducing symptoms caused by weaning or partial weaning of a person away from tobacco or nicotine use
EP0315681B1 (en) Use of nalmefene for the manufacture of a pharmaceutical composition for central nervous system injury treatment
JP2005502633A (ja) ニコチン依存症に対する薬物療法のための活性物質配合体
EP0821959A2 (en) Use of 3-(4-hexyloxy-1,2,5-thiadiazol-3-yl)-1,2,5,6-tetrahydro-1-methylpyridine for treating nicotine withdrawal
US8106074B2 (en) Pyridin-2-yl-methylamine derivatives for treating opiate dependence
Jones COCAINE AND BRAIN FUNCTION
US7261907B2 (en) Compositions for the treatment of neurological disorders
Carney et al. Central Nervous System Drugs
HK1209058B (en) Compositions for treating drug addiction and improving addiction-related behavior

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20040120

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20050207

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20050207

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000